Feeling mild COVID-19 symptoms? For the safety of our community, you do NOT need to visit the emergency department unless critical symptoms are experienced. Visit our COVID-19 hub to learn more. Visit the COVID-19 Hub

Tampa General Hospital’s Hematology Malignancies Program Treats Patients with Benign and Malignant Blood Diseases

Tampa General Hospital’s Hematology Malignancies Program provides diagnostic services and treatment options for patients for all kinds of blood disorders, both cancerous and benign. Our interdisciplinary staff includes physicians from TGMG and USF Health specializing in hematology, as well as registered nurses, medical assistants, and radiation oncologists who can assist in cases of malignant disease. Each patient’s needs are assessed on an individual basis before our team tailors a treatment plan to fit his or her precise situation.

Utilizing the extensive resources available to us, our experienced team can address a number of conditions, including:

  • Bleeding disorders
  • Malignant blood diseases (such as lymphoma, leukemia, and myeloma)
  • Excessive production of blood components (also known as myeloproliferative disorders)
  • Insufficient generation of healthy blood cells (also known as myelodysplastic syndromes)

To provide effective care for patients with these cancer conditions, our hematology malignancies program offers patients state-of-the-art medical treatment with the help of progressive technologies and our compassionate staff members. Some of the treatments that we offer include infusion of blood components or medications for benign and malignant conditions, and chemotherapy for blood cancers like leukemia and lymphoma. We also provide radiation therapy treatments for malignancies, including therapies that use advanced technologies like TomoTherapy®, a form of image-guided, intensity-modulated radiation (IMRT).

TGH Among Top 10% in the Nation for Cancer Care 

Tampa General Hospital has earned “high performing” designation for cancer care by U.S. News & World Report for 2022-23, meaning we are ranked among the top 10% of U.S. hospitals.

Our World-Class Cancer Institute